IntronBio "Collaboration with Osang Healthcare on Molecular Diagnostic Business Including COVID-19 Test Kits"

[Asia Economy Reporter Hyunseok Yoo] Intronbio announced on the 9th that it has signed an agreement with Osang Healthcare, a subsidiary of Osang Jaeil, for strategic business cooperation in the diagnostic and healthcare fields, including the novel coronavirus disease (COVID-19) diagnostic kit business.

The two companies have jointly completed the development of a product that can accurately diagnose the COVID-19 virus, which is increasing worldwide. As diagnosis is expected to increase globally, the two companies plan to actively cooperate in related businesses by combining their capabilities.

Osang Healthcare explained, "The COVID-19 diagnostic kit 'GeneFinder™ COVID-19 Plus RealAMP Kit' qualitatively detects three target genes of COVID-19 (E Gene, RdRp Gene, N Gene)," adding, "We have applied for emergency use authorization from the Korea Disease Control and Prevention Agency, and the review is currently underway." They further added, "We have recently started supplying the COVID-19 diagnostic kit to a global diagnostic company located in Italy, where confirmed cases are rapidly increasing."

Intronbio agreed to supply raw materials (diagnostic materials) for Osang Healthcare's COVID-19 diagnostic kit and to actively cooperate to meet the growing global demand for diagnostic kit supply. They also announced that the developed COVID-19 diagnostic kit from Osang Healthcare has passed the emergency use authorization process by the Italian health authorities.

Lee Donghyun, Chairman of Osang Group, stated, “We hope that the cooperation between the two companies, which possess technological capabilities and global networks, will help wisely overcome this chaotic period in which humanity is threatened worldwide,” emphasizing, “In addition, the two companies have agreed to jointly promote the molecular diagnostics business and collaborate on R&BD development projects in the healthcare field.”

Yoon Kyungwon, CEO of Intronbio, said, “From the perspective of Intronbio, which has been focusing on new drug development after listing on KOSDAQ, cooperation with Osang is an opportunity to establish a more systematic system in the diagnostic field by pioneering new business avenues in the existing molecular diagnostics part,” adding, “Intronbio has also applied for emergency use authorization for the COVID-19 diagnostic kit from the Korea Disease Control and Prevention Agency, but we have decided to prioritize cooperation with Osang Healthcare for global-level supply.”

This content was produced with the assistance of AI translation services.